A fourteen-year partnership between The Babraham Institute and AstraZeneca has contributed to the development of new drugs to treat cancer and new clinical practices in the use of anti-cancer drug combinations.
Researchers at The Babraham Institute, which receives strategic funding from BBSRC, have used their expertise in the signalling pathways that control cell survival and cell division to help AstraZeneca develop anticancer drugs targeting these pathways. This was made possible by BBSRC’s award of a rolling programme of grants to Babraham for fundamental biology research and infrastructure.
Download the pdf or visit the Impact page of the BBSRC website